Mitochondrial Medicine – Therapeutic Development

Virtual

Abliva will attend the virtual conference Mitochondrial Medicine - Therapeutic Development, organized by the Wellcome Connecting Science located at the Wellcome Genome Campus in the UK, on 30 Nov - 2 Dec 2021. Abliva's CMO, Magnus Hansson, has been invited to give a presentation on the topic Academia-pharma interplay in drug development, during Session 1: Mitochondrial […]

Mitochondria-Targeted Drug Development Summit

Hyatt Regency Boston/Cambridge 575 Memorial Dr, Cambridge, Massachusetts, United States

Abliva will attend and present at the Mitochondria-Targeted Drug Development Summit in Boston, MA, USA. The event will be held on 22 - 24 February 2022. CEO Ellen Donnelly will be presenting in the session Patient-Focused Drug Development for Mitochondrial Disease. Synopsis: Highlighting the impact of patient input on research and development at Abliva Providing […]

UMDF’s Mitochondrial Medicine Symposium

JW Marriott Phoenix Desert Ridge Resort & Spa Phoenix, AZ, United States

Abliva will participate at the United Mitochondrial Disease Foundation's Mitochondrial Medicine Symposium in Phoenix, Arizona. Abliva's CMO, Magnus Hansson, will participate in a panel discussion on clinical trials together with Baylor College of Medicine, Cyclerion Therapeutics, and Khondrion, on Friday June 10.

Bioblast 2022: Inaugural Conference of Bioenergetics Communications

Congress Innsbruck Rennweg 3, Innsbruck, Austria

On June 29-30, Abliva will participate at Bioblast 2022: Inaugural Conference of Bioenergetics Communications in Innsbruck, Austria. Abliva's Communications Officer & Lab Manager, Eleonor Åsander Frostner, will present a summary of the company's recent preprint publication "Towards a treatment for mitochondrial disease: current compounds in clinical development".

mitoNice

Nice Acropolis Congress Center Nice, France

In September, Abliva will attend mitoNice, an international congress dedicated to Mitochondrial Medicine.

Mitocon’s Mitochondrial Diseases Conference

Holiday Inn Rome EUR Parco dei Medici Rome, Italy

In October, Abliva will attend the Italian patient organization Mitocon's annual Mitochondrial Diseases Conference in Rome, Italy. On October 8, Abliva's Chief Medical Officer Magnus Hansson will give the talk: An adaptive, clinical Phase 2/3 study evaluating the efficacy of KL1333 in adult primary mitochondrial disease patients in Session 5: Challenges and pitfalls in clinical […]

Mitochondrial Medicine – Therapeutic Development

Wellcome Genome Campus Hinxton, United Kingdom

In late November, Abliva will attend the annual scientific conference Mitochondrial Medicine - Therapeutic Development in Hinxton, UK. Abliva's Chief Medical Officer, Magnus Hansson, will present a poster on one of the important preparatory studies for the upcoming, potentially registrational, Phase 2 study, FALCON, with KL1333 in patients with mitochondrial diseases.

Euromit 2023

Bologna Congress Center Piazza della Costituzione, 4/a, Bologna, Italy

In June, Abliva will attend this year's edition of Euromit - the international conference on mitochondrial disease. The meeting takes place in Bologna, Italy, and gathers researchers, clinicians, and patients for the sharing of knowledge and insights in the field. The conference also presents opportunities to meet with investigators in our FALCON study with KL1333.

UMDF’s Mitochondrial Medicine Symposium 2023

Sheraton Charlotte Hotel/Le Méridien 555 SOUTH MCDOWELL STREET, Charlotte, NC, United States

In late June, Abliva will be attending this year's international Mitochondrial Medicine Symposium, organized by US patient organization United Mitochondrial Disease Foundation. The meeting will take place in Charlotte, North Carolina (US), on June 28 - July 1, and includes both scientific as well as patient and family sessions.

The Future of Swedish & Danish Life Science

Restaurant Inspira Scheelevägen 4, Lund, Sweden

Abliva will participate at the 12th annual edition of 'The Future of Swedish & Danish Life Science', on September 7, 2023, in Lund, Sweden. The company's Chief Medical Officer, Magnus Hansson, will give a talk entitled Pivotal study design in a rare disease with no regulatory precedent – utilizing patient advocacy groups and registries. "The […]

Empower & Inspire – 2nd Annual Leigh Syndrome Symposium

Virtual

During World Mitochondrial Disease Week, Abliva's Chief Medical Officer, Magnus Hansson, will present the company at the Cure Mito Foundation's Empower & Inspire - 2nd Annual Leigh Syndrome Symposium (virtual). See below for more information and the link to the event.

Mitochondrial Medicine – Therapeutic Development

In mid-March, Abliva will attend the 8th edition of Mitochondrial Medicine - Therapeutic Development in Hinxton, UK. This annual scientific meeting is focused on mitochondrial disorders and the search for novel effective therapies. Abliva's CMO, Maguns Hansson, will join the panel discussion Challenges and opportunities in clinical trials: perspectives from pharma and funders, where representatives from […]